Category Archives: breast cancer

Endocr Relat Cancer

Endocr Relat Cancer. 2006 Jun;13(2):583-92.
Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE.
Continue reading

Estrogen and Breast Cancer: Women suffer estrogen deprivation due to a medical community that disregards a safe alternative.

In September 2012, a jury in Salt Lake City, Utah awarded a breast cancer survivor $5.1 million in a court case against the pharmaceutical company, Wyeth (also known as Pfizer), alleging that the use of Premarin-Provera (Prempro) was responsible for the development of her breast cancer.1 This is one of many lawsuits against Wyeth, since the Women’s Health Initiative trial (WHI) was published in 2002. The general matter for this case is whether Wyeth withheld data and failed to inform the public concerning the risk of breast cancer with the use of the synthetic hormones, Prempro. There have been over 10,000 cases filed against Wyeth, which has paid $896 million to resolve over 6,000 lawsuits. Furthermore, they have set aside an additional $330 million to resolve the remaining lawsuits.
Continue reading

Inflammation and Breast Cancer mortality

In a study conducted by Cornelia Ulrich, Ph.D. and colleagues from the Cancer Prevention Program at the Fred Hutchinson Cancer Research Center in Seattle, elevated levels of two proteins in the blood – C-reactive protein (CRP) and serum amyloid A (SAA) – were found to be associated with overall survival rates in patients with breast cancer. The study involved 734 breast cancer patients, with data drawn from the Health, Eating, Activity and Lifestyle (HEAL) study, a multi-ethnic National Institutes of Health-funded prospective group of women diagnosed with Stage 0 to Stage IIIa breast cancer. Measurements of the CRP and SAA proteins were taken 31 months after initial diagnosis.

The researchers found that those women with the top-third highest levels of SAA were three times more likely to die from their disease within the following seven years compared to the group of patients in the lowest third. They also found a two-fold increased risk of death in women with the top-third highest levels of CRP.

Continue reading

Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells

Mol Cell Endocrinol. 2010 May 14;320(1-2):162-70. Epub 2010 Feb 6.
Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M.
Dipartimento Farmaco-Biologico, Università della Calabria, Rende (CS), Italy.
Continue reading